ADAP Adaptimmune Therapeutics plc -

4.26
-0.25  -5.54%
Previous Close 4.51
Open 4.53
Price To book 1.77
Market Cap 301.54M
Shares 70,785,000
Volume 137,997
Short Ratio 3.43
Av. Daily Volume 149,053

SEC filingsSee all SEC filings

  1. 8-K - Current report 17516519
  2. 8-K - Current report 17515870
  3. 8-K - Current report 162059534
  4. 8-K - Current report 162032675
  5. 8-K - Current report 162018361

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 to be initiated 2H 2017.
NY-ESO T-cell therapy
Synovial sarcoma - cancer
Further trials planned for 2H 2016
NY-ESO T-cell therapy
Ovarian cancer
Pivotal trial placed on clinical hold due to non-safety issues. Hold released November 2016. Envisage initiation 4Q 2016 or 1Q 2017
NY-ESO T-cell therapy
Myxoid round cell liposarcoma (MRCLS)
Further trials planned for 1H 2017.
NY-ESO T-cell therapy
Myeloma
Phase 1/2 initiated November 2015. Data are due 2017.
NY-ESO T-cell therapy
Non-small cell lung cancer (NSCLC)

Latest News

  1. ADAPTIMMUNE THERAPEUTICS PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  2. Adaptimmune confirms GSK Nomination of Second Adaptimmune Target under Strategic Multi-Target Collaboration
  3. Adaptimmune Announces New Senior Vice President of Global Bio-Process and Development
  4. Adaptimmune Announces FDA Acceptance of IND Application for Affinity Enhanced T-Cell Therapy Targeting MAGE-A4 in Multiple Solid Tumors
  5. These 5 Stocks Under $10 Could Make You a Lot of Money
  6. ADAPTIMMUNE THERAPEUTICS PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial
  7. Adaptimmune and Bellicum Pharmaceuticals Enter a Strategic Collaboration to Evaluate Next-Generation T-Cell Therapies
  8. Adaptimmune and Bellicum Pharmaceuticals Enter a Strategic Collaboration to Evaluate Next-Generation T-Cell Therapies
  9. Adaptimmune and Bellicum Pharmaceuticals Enter a Strategic Collaboration to Evaluate Next-Generation T-Cell Therapies
  10. Is Adaptimmune Therapeutics PLC (ADAP) A Good Stock To Buy?
  11. How Verso Corporation (VRS) Stacks Up Against Its Peers
  12. ADAPTIMMUNE THERAPEUTICS PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  13. Adaptimmune Announces Initiation of Myxoid/Round Cell Liposarcoma Study
  14. Adaptimmune Announces Initiation of Myxoid/Round Cell Liposarcoma Study
  15. ADAPTIMMUNE THERAPEUTICS PLC Files SEC form 8-K, Termination of a Material Definitive Agreement
  16. ADAPTIMMUNE THERAPEUTICS PLC Financials
  17. ADAPTIMMUNE THERAPEUTICS PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  18. Adaptimmune Announces Update on Clinical Data from NY-ESO SPEAR™ T-cell Synovial Sarcoma Study at the 2016 Annual Meeting of the Connective Tissue Oncology Society (CTOS)
  19. Edited Transcript of ADAP earnings conference call or presentation 10-Nov-16 1:00pm GMT
  20. Adaptimmune Presents Preclinical Data from a New, Wholly-owned SPEAR™ T-cell and a Second Generation SPEAR T-cell at the 31st Annual Meeting of the Society for Immunotherapy for Cancer (SITC)

SEC Filings

  1. 8-K - Current report 17516519
  2. 8-K - Current report 17515870
  3. 8-K - Current report 162059534
  4. 8-K - Current report 162032675
  5. 8-K - Current report 162018361
  6. 8-K - Current report 161990129
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 161986247
  8. 8-K - Current report 161985924
  9. 8-K - Current report 161984549
  10. 8-K - Current report 161981762